Generation of self-peptides to treat systemic lupus erythematosus

Methods in Molecular Biology

Volumn 1134, Issue , 2014, Pages 173-192

  Briand, Jean Paul ^a   Schall, Nicolas ^a   Muller, Sylviane ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cytokines assays; MHC peptide binding assay; Murine models of lupus; P140 peptide; Systemic lupus erythematosus; Therapeutic peptides

Indexed keywords

AUTOANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SODIUM CHLORIDE; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BINDING; DRUG EFFICACY; DRUG PURIFICATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EX VIVO STUDY; FEMALE; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE MODEL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; AUTOANTIGENS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; PEPTIDES; PROTEIN BINDING;

EID: 84896270891     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0326-9_13     Document Type: Article

References (45)

1. Zompra AA, Galanis AS, Werbitzky O, Albericio F (2009) Manufacturing peptides as active pharmaceutical ingredients. Future Med Chem 1:361-377
2. Briand JP, Muller S (2005) Synthetic peptides for the analysis of B-cell epitopes in autoantigens. In: Pollard KM (ed) Autoantibodies and autoimmunity: molecular mechanisms in health and disease. Weinheim, Wiley-VCH, pp 189-224
3. Gentilucci L, De Marco R, Cerisoli L (2010) Chemical modifi cations designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des 16:3185-3203
4. Partidos CD, Beignon AS, Semetey V, Briand JP, Muller S (2001) The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine 19:2708-2715
5. Briand JP, Muller S (2010) Emerging peptide therapeutics for infl ammatory autoimmune diseases. Curr Pharm Des 16:1136-1142
6. Schall N, Page N, Macri C, Chaloin O, Briand JP, Muller S (2012) Peptide-based approaches to treat lupus and other autoimmune diseases. J Autoimmun 39:143-153
7. Steinman L, Merrill JT, Mcinnes IB, Peakman M (2012) Optimization of current and future therapy for autoimmune diseases. Nat Med 18:59-65
8. Zimmer R, Scherbarth HR, Rillo OL, Gomez- Reino JJ, Muller S (2013) Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebocontrolled phase IIb clinical trial. Ann Rheum Dis 72:1830-1835
9. Neimark J, Briand JP (1993) Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. Pept Res 6:219-228
10. Merrifi eld RB (1963) Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85:2149-2154
11. Carpino LA, Han GY (1970) The 9- fl uorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J Am Chem Soc 92:5748-5749
12. Monneaux F, Muller S (2000) Laboratory protocols for the identifi cation of Th cell epitopes on self-antigens in mice with systemic autoimmune diseases. J Immunol Methods 244:195-204
13. Baker PE, Gillis S, Smith KA (1979) Monoclonal cytolytic T-cell lines. J Exp Med 149:273-278
14. Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE (1989) Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol 142:800-807
15. Breen EC, Reynolds SM, Cox C, Jacobson LP, Magpantay L, Mulder CB et al (2011) Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol 18:1229-1242
16. Lash GE, Scaife PJ, Innes BA, Otun HA, Robson SC, Searle RF et al (2006) Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. J Immunol Methods 309:205-208
17. Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J et al (2004) Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110:252-266
18. Dali H, Busnel O, Hoebeke J, Bi L, Decker P, Briand JP et al (2007) Heteroclitic properties of mixed alpha- and aza-beta3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome. Mol Immunol 44:3024-3036
19. Mézière C, Stockl F, Batsford S, Vogt A, Muller S (1994) Antibodies to DNA, chromatin core particles and histones in mice with graft-versus- host disease and their involvement in glomerular injury. Clin Exp Immunol 98:287-294
20. Monneaux F, Briand JP, Muller S (2000) B and T cell immune response to small nuclear ribonucleoprotein particles in lupus mice: autoreactive CD4(+) T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein. Eur J Immunol 30:2191-2200
21. Nagata S, Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43
22. Cohen PL, Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-269
23. Theofi lopoulos AN, Dixon FJ (1985) Murine models of systemic lupus erythematosus. Adv Immunol 37:269-390
24. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S (2003) T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 33:287-296
25. Page N, Gros F, Schall N, Décossas M, Bagnard D, Briand JP et al (2011) HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis 70:837-843
26. Fournel S, Neichel S, Dali H, Farci S, Maillère B, Briand JP et al (2003) CD4+ T cells from (New Zealand Black x New Zealand White) F1 lupus mice and normal mice immunized against apoptotic nucleosomes recognize similar Th cell epitopes in the C terminus of histone H3. J Immunol 171:636-644
27. Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178-J206
28. Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specifi c therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162:5775-5783
29. Suen JL, Chuang YH, Tsai BY, Yau PM, Chiang BL (2004) Treatment of murine lupus using nucleosomal T cell epitopes identifi ed by bone marrow-derived dendritic cells. Arthritis Rheum 50:3250-3259
30. Dumortier H, Monneaux F, Jahn-Schmid B, Briand JP, Skriner K, Cohen PL et al (2000) B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol 165:2297-2305
31. Dieker JW, Fransen JH, Van Bavel CC, Briand JP, Jacobs CW, Muller S et al (2007) Apoptosisinduced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 56:1921-1933
32. Plaué S, Muller S, Van Regenmortel MH (1989) A branched, synthetic octapeptide of ubiquitinated histone H2A as target of autoantibodies. J Exp Med 169:1607-1617
33. Van Bavel CC, Dieker JW, Kroeze Y, Tamboer WP, Voll R, Muller S et al (2011) Apoptosisinduced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Ann Rheum Dis 70:201-207
34. Dieker J, Muller S (2010) Epigenetic histone code and autoimmunity. Clin Rev Allergy Immunol 39:78-84
35. Woppmann A, Patschinsky T, Bringmann P, Godt F, Lührmann R (1990) Characterisation of human and murine snRNP proteins by twodimensional gel electrophoresis and phosphopeptide analysis of U1-specifi c 70K protein variants. Nucleic Acids Res 18:4427-4438
36. Woppmann A, Will CL, Kornstadt U, Zuo P, Manley JL, Lührmann R (1993) Identifi cation of an snRNP-associated kinase activity that phosphorylates arginine/serine rich domains typical of splicing factors. Nucleic Acids Res 21:2815-2822
37. Perry D, Sang A, Yin Y, Zheng YY, Morel L (2011) Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011: 271694
38. Monneaux F, Dumortier H, Steiner G, Briand JP, Muller S (2001) Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice. Int Immunol 13:1155-1163
39. Schroeder MA, Dipersio JF (2011) Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech 4:318-333
40. Rottman JB, Willis CR (2010) Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. Vet Pathol 47:664-676
41. Dixon FJ (1981) Murine systemic lupus erythematosus. Immunol Today 2:8-9
42. Guillet JG, Lai MZ, Briner TJ, Buus S, Sette A, Grey HM et al (1987) Immunological self, nonself discrimination. Science 235:865-870
43. Lai MZ, Ross DT, Guillet JG, Briner TJ, Gefter ML, Smith JA (1987) T lymphocyte response to bacteriophage lambda repressor cI protein. Recognition of the same peptide presented by Ia molecules of different haplotypes. J Immunol 139:3973-3980
44. Mézière C, Viguier M, Dumortier H, Lo-Man R, Leclerc C, Guillet JG et al (1997) In vivo T helper cell response to retro-inverso peptidomimetics. J Immunol 159:3230-3237
45. Ngo-Giang-Huong N, Kayibanda M, Deprez B, Levy JP, Guillet JG, Tilkin AF (1995) Mutations in residue 61 of H-Ras p21 protein infl uence MHC class II presentation. Int Immunol 7:269-275